Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Jefferies Global Healthcare Conference 2024
12 slides from Mayne Pharma's conference presentation, Jun 6, 2024
Slide 1: ASX Announcement: Mayne Pharma presentation at Jefferies Global Healthcare Conference
ASX Announcement MAYNE PHARMA PRESENTATION AT THE 2024 JEFFERIES GLOBAL HEALTHCARE CONFERENCE, NEW YORK CITY 06 June 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the 2024 Jefferie
Slide 2: Mayne Pharma Group Limited - Jefferies Global Healthcare Conference
For personal use only Mayne Pharma Group Limited MYX.ASX Jefferies Global Healthcare Conference June 6, 2024 Shawn Patrick O’Brien CEO and Managing Director
Slide 3: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential inves
Slide 4: Mayne Pharma: Improving patient access to life-enhancing medications
Mayne Pharma: Improving patient access to life-enhancing medications ● Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing For personal use only branded pharmaceuticals. Women’s Health Dermatology International Reproductive Health Proprietary Brands • Flagship p
Slide 5: Why Mayne Pharma?
Why Mayne Pharma? Leading position in strong and growing Women’s Health market 4 novel products For personal use only One of the top 2 specialised women’s health companies in the US1 Building market leadership and scale in Dermatology 6 proprietary brands and 20+ AGs & generic dermatologics Portfoli
Slide 6: FY2024 Goals
FY2024 Goals For personal use only Deliver positive Optimize cost base Return Company to Return Company to direct contribution1 with OPEX and NEXTSTELLIS® run positive operating positive underlying in all three other reductions of rate breakeven cash generation in EBITDA in FY24 segments >US$10m FY2
Slide 7: US Women's Health 1HFY24 Performance
US Women’s Health 1HFY24 Performance +45% revenue growth For personal use only ● A leading position in strong and growing market Women's Health in USD'000 1HFY23 2HFY23 1HFY24 with four novel women’s healthcare products Total Revenue 9,005 32,667 47,277 ● One of the top 2 specialized women’s healt
Slide 8: Dermatology / Portfolio Products Division 1HFY24 Performance
Dermatology / Portfolio Products Division (PPD) 1HFY24 Performance For personal use only +71% revenue growth Derm in USD'000 1HFY23 2HFY23 1HFY24 ● 6 proprietary brands and 20 generic dermatologics Total Revenue 7,495 30,878 52,855 ● Portfolio can fill 1 in 3 US Dermatology Retail Rx’s1 Total Gross
Slide 9: Patient Ease of Access or Disintermediation Strategy
Patient Ease of Access or Disintermediation Strategy Mayne Pharma’s unique platform spans the entire value chain, allowing for the ability to create a comprehensive, frictionless, transparent, and cost-effective experience For personal use only ● Launched pilot program with GoodRx in 1HFY24 in Derma
Slide 10: International 1HFY24 Performance
International 1HFY24 Performance For personal use only ● Improved financial profile International in AUD'000 1HFY23 2HFY23 1HFY24 ● 2-year agreement signed for the supply of Reported Revenue 27,626 37,079 34,608 BETADINE® Reported Gross Profit 8,876 10,048 10,480 ● Expansion of KADIAN® /KAPANOL® int
Slide 11: 2HFY24 Outlook and Key Focus
2HFY24 Outlook and Key Focus Expected to grow both revenue and earnings 2H24 vs. 1H24 For personal use only WOMEN’S HEALTH DERMATOLOGY Continued revenue growth with improving • Continued growth across all Women’s • Maintenance of margin profile via more cost leverage and Health brands, continued ope
Slide 12: Fireside Chat Q&A
Fireside Chat Q&A For personal use only Shawn Patrick O’Brien CEO Mayne Pharma Group Limited ASX:MYX You deserve tomorrow. 11
Mayne Pharma Group — Jefferies Global Healthcare Conference 2024 on 6ix